Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer

Summary

The goal of the present study is to test if in situations of borderline resectable patients a neoadjuvant treatment combining Gemzar-Abraxane and stereotactic radiosurgery could increase the median OS rates above 30 months that means at least 12 months more than the 18-20 months generally described.

Timeline

Start

2017-04-20

Primary completion

2021-03-19

Completion

2021-03-19

Outcome

Outcome not reported

Stopped (Enrollment): “difficulties to recruit patients”

Drugs

Indications